Dodge & Cox Has $969.27 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Dodge & Cox grew its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 6.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,746,235 shares of the biotechnology company's stock after buying an additional 847,917 shares during the period. Dodge & Cox owned approximately 7.74% of BioMarin Pharmaceutical worth $969,270,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund lifted its holdings in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock worth $2,546,000 after buying an additional 164 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of BioMarin Pharmaceutical by 13.9% during the 4th quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock worth $89,000 after purchasing an additional 165 shares during the period. TD Private Client Wealth LLC raised its position in shares of BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after buying an additional 186 shares during the last quarter. First Hawaiian Bank lifted its position in shares of BioMarin Pharmaceutical by 1.4% in the 4th quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock worth $966,000 after acquiring an additional 200 shares during the period. Finally, CIBC Private Wealth Group LLC increased its position in shares of BioMarin Pharmaceutical by 64.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 233 shares during the period. Institutional investors own 98.71% of the company's stock.

Wall Street Analyst Weigh In

BMRN has been the topic of several recent research reports. Citigroup lifted their target price on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Scotiabank raised their target price on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research report on Thursday, February 20th. StockNews.com lowered BioMarin Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Finally, Bank of America boosted their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $68.38, for a total transaction of $91,902.72. Following the completion of the transaction, the chief accounting officer now directly owns 13,105 shares of the company's stock, valued at $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.85% of the company's stock.

BioMarin Pharmaceutical Trading Up 0.6 %

BMRN traded up $0.35 during mid-day trading on Friday, hitting $59.17. The stock had a trading volume of 1,247,162 shares, compared to its average volume of 1,886,222. BioMarin Pharmaceutical Inc. has a 1-year low of $52.93 and a 1-year high of $94.85. The firm has a market capitalization of $11.29 billion, a price-to-earnings ratio of 26.90, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The stock's fifty day simple moving average is $66.74 and its 200-day simple moving average is $66.25.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. As a group, research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.